올릭스
90,600KRWMarket close of 10/27 (Tue)
Down -5.72%-5,500KRWMarket close of 10/27 (Tue)
Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)97,300KRWUp +7.40%
Preliminary · replaced once official KRX data for the same date is published
- Open
- 97,200
- High
- 100,800
- Low
- 86,600
- Day range
- Day range low 86,600 high 100,800, open 97,200, close 90,600, previous close 96,100
- Volume
- 26×10K shares
- 24.1B KRW 1.02× the 20-session average
Market close of 10/27 (Tue)
Where it sits in the 1-year range
3%1-year close range 87,300 to 207,000 won, 3% up from the low
3% of the way up from the lowest close in 1 year (252 sessions) · -56.2% from the high
Loading
Free · no sign-inSource from 2021-05-17
Data dateMost recent closing data10/27 (Tue)
Market close data of 2026-10-27Points to check
- Earningsto check-41.6B KRWOperating income over the last four quarters -41.6B KRW (loss)
- Recent filingsnot verifiedCould not read filing data, so not verified
- Daily moveusual range-5.72%-5.72%, 1.2× the usual (20-session average ±4.83%)That day -5.72% · usual ±4.83% · large-move threshold ±9.7%
The other 2 are within the usual range
- Trading value1.0×usual range
- Foreign & institutional+1.1B KRWusual range
See the full check report
Same sector · 바이오 R&D
Down -0.67%· 26 of 64 stocks up, preferred shares excluded · trading value 190.2B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -12.6% | Flat 0.00% | 51.8B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -8.3% | Up +0.37% | 14.0B KRW |
| 리가켐바이오 | Close over the last 20 sessions -20.9% | Down -1.54% | 12.1B KRW |
| 페니트리움바이오 | Close over the last 20 sessions -4.2% | Up +14.41% | 9.8B KRW |
| 보로노이 | Close over the last 20 sessions -19.3% | Down -2.86% | 8.9B KRW |
Schedule
- Q3 report due · 11/16 (Mon) · in 18 days
- Next data 10/29 (Thu) after 08:50
Related news
Loading
Tables, financials, investor flows and filing history are in the Detailed view.
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.